Phase 1/2 AlphaBet Trial: Promising Combination of Lutetium-177 PSMA-I&T and Radium-223 in Advanced Prostate Cancer

/in , , , /by

A novel therapeutic approach combining lutetium-177 177Lu-PSMA-I&T and radium-223 (223Ra) shows encouraging results for men with metastatic castration-resistant prostate cancer (mCRPC), as demonstrated in the recently reported AlphaBet trial published in The Lancet Oncology in October 2025. This phase 1/2 AlphaBet study is the first to evaluate the safety, feasibility, and preliminary efficacy of the […]

Read more

Phase 1/2 PETRANHA Trial Update: Promising Results Reported at ESMO 2025

/in , , , /by

At the 2025 ESMO Congress, new data from the phase 1/2 PETRANHA trial introduced saruparib (AZD5305), a highly selective PARP1 inhibitor, as a potentially safer and more effective therapeutic partner for androgen receptor pathway inhibitors (ARPIs) in metastatic prostate cancer. The results highlighted a strong efficacy signal in castration-sensitive disease and ARPI-naïve castration-resistant settings, while […]

Read more

UPDATE: Phase 1 Trial of Alpha Radioligand Therapy AB001 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

/in , , /by

A new Phase 1 clinical study, known as the ARTISAN trial, is evaluating an investigational lead-212 alpha radioligand therapy targeting prostate-specific membrane antigen (PSMA) in men with metastatic castration-resistant prostate cancer (mCRPC). We discussed AB001 in a previous article; the trial has now been approved, and its full details are available. The therapy combines a […]

Read more

Phase 1/2 Study: New Combination Therapy Combines Tulmimetostat (DZR123) and JSB462 (aka Luxdegalutamide aka ARV-766)

/in , , , /by
Read more